Building the infrastructure layerfor tech-enabled drug discovery
We are the only biotechnology company advancing small and large molecule drug discovery with a multimodal AI platform powered by laboratory automation.
We integrate AI with three proprietary data streams – computational data, wet lab proxy biological data, and wet lab ground truth biological data – to deliver novel drug candidates and software solutions to leading pharma and tech partners, and advance our internal pipeline for neurological, autoimmune diseases, and cancer.
![](/images/new/vision.png)
![Microsoft](/images/home/investors/m12-2.png)
![Playground Global](/images/home/investors/pg.png)
![FoundersX](/images/home/investors/fx-2.png)
![Y Combinator](/images/home/investors/yc-2.png)
![Scientia Ventures](/images/home/investors/sv.jpeg)
![Sam Altman. CEO, OpenAI](/images/home/investors/sam.png)
![Business Insider](https://1910genetics-2020.s3.amazonaws.com/bi_53dd4517f8.png)
![WSJ](https://1910genetics-2020.s3.amazonaws.com/Venture_Capital_53337f61a8.png)
![Microsoft Blog](https://1910genetics-2020.s3.amazonaws.com/ms_5887859af4.png)
![TC](https://1910genetics-2020.s3.amazonaws.com/Tech_Crunch_Logo_2011_f87fbb5a6a.png)
![GEN](https://1910genetics-2020.s3.amazonaws.com/gn_dc8d7a642b.png)
Want more insights? Check out our posts.
Have a lookAccenture Collaborates with 1910 Genetics to Help Biopharma Companies Transform Drug Discovery with AI
4m read 31st October, 2024.
1910 Genetics Launches CANDID-CNS™, an AI Model for Blood-Brain Barrier Permeability Prediction that Outperforms the Industry Standard
5m read 17th October, 2024.
Microsoft partners with Boston biotech to build 'drug discovery on steroids'
3m read 29th April, 2024.